Chronic myelogenous leukemia: An update on the biological findings and therapeutic approaches

Critical Reviews in Oncology/Hematology

Volumn 22, Issue 3, 1996, Pages 151-174

  Ferrajoli, Alessandra ^a   Fizzotti, Marco ^a   Liberati, Anna Marina ^a   Grignani, Fausto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CHLORAMBUCIL; HYDROXYUREA; MELPHALAN; MERCAPTOPURINE; MITOBRONITOL;

ADDISON DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANOREXIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CHRONIC MYELOID LEUKEMIA; FATIGUE; FEVER; HEART MUSCLE FIBROSIS; HUMAN; LEUKEMOGENESIS; LUNG FIBROSIS; MULTIMODALITY CANCER THERAPY; REVIEW; TACHYPHYLAXIS;

EID: 0029954364     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(96)00192-8     Document Type: Review

References (253)

1. Baikie AG. Cytogenetic studies in familiar leukemias. Aust. Ann. Med. 18:7-10, 1969.
2. Jacobs EM. Chromosome abnormalities in human cancer: report of a patient with chronic myelocytic leukemia and his non-leukemic monozygotic twin. Cancer 19:869-871, 1966.
3. Haas OA, Argyriou-Tirita A, Lion T. Parental origin of chromosomes involved in the translocation t(9;22). Nature 359:414-416, 1992.
4. Riggins GJ, Zhang F, Warren ST. Lack of imprinting of BCR. Nat Genet 6:226, 1994.
5. Fioretos T, Heisterkamp N, Groffen J. No evidence for genomic imprinting of the human BCR gene. Blood 83:3441-3444, 1994.
6. Litz CE, Copenhaver CM. Paternal origin of the rearranged major breakpoint cluster region in chronic myeloid leukemia. Blood 83:3445-3448, 1994.
7. Chang J, Geary CG. Therapy-linked leukemia. Lancet 1:519-525, 1977.
8. Bizzozzero OJ, Johnson KG, Ciocco A. Radiation related leukemia in Hiroshima and Nagasaki, 1946-1964. Distribution, incidence and appearance time. N Engl J Med 274:1095-2101, 1966.
9. Mole RH. Ionizing radiations and human leukemia. In Henderson ES and Lister TA. eds. Leukemia, 5th Edn. Philadelphia: WB Saunders Company, 1990; 253-259.
10. Travis LB, Li C-Y, Zhang Z-N, Li D-G, Yin S-N, Chow W-H, et al. Hematopoietic malignancies and related disorders among benzene-exposed workers in China, Leuk Lymph 14:91-102, 1994.
11. Young JL, Percy CL, Asire AJ (eds). SEER: Incidence and mortality data: 1973-1977. Natl Cancer Inst Monogr 57, NIH Publication No. 81; 1981.
12. Cartwright RA, Alexander FE, McKinney PA, Ricketts JT. Leukaemia research fund data collection survey: descriptive epidemiology of chronic myeloid leukaemia. Leukemia 5:138-141, 1991.
13. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 132:1497-1500, 1960.
14. Caspersson T, Gahrton G, Lindsten J, Zech L. Identification of the Philadelphia chromosome on a number 22 by quinacrine mustard fluorescence analysis. Exp Cell Res 63:238-240, 1970.
15. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine, fluorescence and Giemsa staining. Nature 243:290-293, 1970.
16. Fialkow JP, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 58:158-161, 1981.
17. Fialkow JP. Cell lineages in hematopoietic neoplasia studied with glucose-6-phosphate dehydrogenase cell markers. Cell Physiol 1(Suppl 1):37-42, 1982.
18. Fialkow JP, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 63:125-130, 1977.
19. Fialkow JP, Denman AM, Jacobson RJ, Lowenthal MN. Chronic myelocytic leukemia: origin of some lymphocytes from leukemic stem cells. J Clin Invest 62:815-820, 1978.
20. Fialkow JP. Clonal and stem cell origin of blood neoplasms. In: Lobue J, Gordon AS, Silber R, Muggia FM, eds. Contemporary Hematology/Oncology, Vol. 1, New York: Plenum Press, 1980.
21. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurta van Kessel A, Bootsma D, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature 306:277-280, 1983.
22. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, et al. Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukaemia. Nature 306:239-242, 1983.
23. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosvelt G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93-99, 1984.
24. Shtivelman E, Lifshitz B, Gale RP, Canaani E, Fused transcript of abl and bcr genes in chronic myeloid leukaemia. Nature 315:550-554, 1985.
25. Hoffman FM, Fresco LD, Hoffman-Falk H, Shilo BZ. Nucleotide sequences of the Drosophila src and abl homologs: conservation and variability in the src family oncogenes. Cell 35:393-401, 1983.
26. Rosenberg N, Witte ON. The viral and cellular forms of the Abelson (abl) oncogene. Adv Virus Res 35:39-81, 1988.
27. Goff SP, Gilboa E, Witte ON, Baltimore D. Structure of the Abelson murine leukemia virus genoma and the homologous cellular gene: studies with clonal viral DNA. Cell 22:777-785, 1980.
28. Abelson HT, Rabstein LS. Lymphosarcoma: virus-induced thymic independent disease in mice. Cancer Res 30:2213-2222, 1970.
29. Shtivelman E, Liftshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 47:277-284, 1986.
30. Bernards A, Rubin CM, Westbrook CA, Paskind M, Baltimore D. The first intron in the human abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia. Mol Cell Biol 7:3231-3236, 1987.
31. Ben-Neriah Y, Bernards A, Paskind M, Daley GQ, Baltimore D. Alternative 5′ exons in c-abl mRNA. Cell 44:577-586, 1986.
32. Franz WM, Berger P, Wang JYJ. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activate its oncogenic potential. EMBO J 8:137-147, 1989.
33. Daley GQ, Ben Neriah Y. Implicating the bcr/abl in the pathogenesis of Philadelphia chromosome-positive human leukemia. Adv. Cancer Res 57:151-184, 1991.
34. Konopka JB, Witte ON. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 5:3116-3123, 1985.
35. Tybulewicz VLJ, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65:1153-1163, 1991.
36. ml mutation show poor viability and depletion of selected B and T cell population. Cell 65:1165-1171, 1991.
37. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocations. Nature 315:758-761, 1985.
38. Hariharan IK, Adams JM. C-DNA sequence for human bcr, the gene that translocates to the abl oncogene in chronic myeloid leukemia. EMBO J 6:1115-1119, 1987.
39. Stam K, Heisterkamp N, Reynold FH, Groffen J. Evidence that the bcr gene encodes a 160 000-Dalton phosphoprotein with associated kinase activity. Mol Cell Biol 7:1955-1960, 1987.
40. rac. Nature 351:400-402, 1991.
41. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukaemias. N Engl J Med 15:990-998, 1988.
42. Gale RP, Canaani E. An 8 kilobase abl RNA transcript in chronic myelogenous leukemia. Proc Natl Acad Sci USA 81:5648-5652, 1984.
43. Stam K, Heisterkamp N, Grosveld G, de Klein A, Verma RS, Coleman M, et al. Evidence for a new chimeric bcr-abl mRNA in patients with chronic myelogenous leukemia and the Philadelphia chromosome. N Engl J Med 313:1429-1433, 1985.
44. Konopka JB, Watanabe SM, Singer JW, Collins SJ, Witte ON. Cell lines and clinical isolates derived from Ph positive chronic myelogenous leukemia patients express abl proteins with a common structural alteration. Proc Natl Acad Sci USA 82:1810-1814, 1985.
45. Hermans A, Heisterkamp N, van Linden M, van Baal S, Meijer D, van der Plas D. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 51:33-40, 1987.
46. Kurzrock R, Shtalrid M, Romero R, Kloetzer WS, Talpaz M, Trujillo JM, et al. A novel c-abl protein product in Philadelphiapositive acute lymphoblastic leukemia. Nature 325:631-635, 1987.
47. Clark SS, Mc Laughlin J, Crist WM, Champlin TR, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph positive CML from Ph positive ALL. Science 235:85-88, 1987.
48. Kurzrock R, Kloetzer WS, Talpaz M. Identifications of molecular variants of P210 bcr-abl in chronic myelogenous leukemia. Blood 70:233-236, 1987.
49. Rosenberg N, Baltimore D, Scher CD. In vitro transformation of lymphoid cells by abelson murine leukemia virus. Proc Natl Acad Sci USA 72:1932-1936, 1975.
50. Young JC, Witte ON. Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures. Mol Cell Biol 8:4079-4087, 1988.
51. Daley GQ, Baltimore D. Transformation of an interleukin-3-dependent hemopoietic cell line by the chronic myelogenous leukemia-specific P210 bcr/abl protein. Proc Natl Acad Sci USA 85:9312-9316, 1988.
52. McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR/ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol 9:1866-1874, 1989.
53. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079-1082, 1990.
54. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hemopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 84:6558-6562, 1987.
55. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830, 1990.
56. Kelliher MA, Knott A, Mc Laughlin J, Rosenberg N, Witte ON. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR-ABL oncogene. Mol Cell Biol 11:4710-4716, 1991.
57. Hariharan IK, Harris AW, Crawford M, Abud H, Webb E, Cory S, Adams JM. A bcr-v-abl oncogene induces lymphomas in transgenic mice. Mol Cell Biol 9:2798-2805, 1989.
58. Heisterkamp N, Jenster J, Ten Hoeve J, Zovich D, Pattengale PF, Groffen J. Acute leukemia in bcr/abl transgenic mice. Nature 344:251-253, 1990.
59. Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR, Witte ON. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 11:1785-1792, 1991.
60. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON, Bcr sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66:161-171, 1991.
61. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175-185, 1993.
62. McWhirter JR, Wang JYJ. Activation of tyrosine kinase and microfilament-binding function of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 11:1553-1556, 1991.
63. Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58:669-678, 1989.
64. Wetzel M, Talpaz M, Van Etten R, Hirsh-Ginsberg C, Beran M, Kurzrock R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 92:1925-1939, 1993.
65. McWhirter JR, Wang JYJ. An actin binding function contributes to transformation by the bcr-abl oncoprotein of Philadelphia chromsome positive human leukemias. EMBO J 12:1533-1546, 1993.
66. Melo JV, Gordon DE, Cross NCP, Goldman JM. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 81:158-165, 1993.
67. Canellos GR, Whang-Peng J, De Vita VT. Chronic granulocytic leukemia without the Philadelphia chromosome. Am J Clin Pathol 65:467-470, 1976.
68. Bartram CR, Carbonell F. Bcr rearrangment in Ph-negative CML. Cancer Genet Cytogenet 21:183-184, 1986.
69. Ganesan TS, Rassool F, Guo AP, Th'ung KH, Dowding C, Hibbin JA, et al. Rearrangment of the bcr gene in Philadelphia chromosome-negative chronic myeloid leukemia. Blood 68:957-960, 1986.
70. Morris CM, Reeve AE, Fitzgerald PH. Hollings PE, Beard MEJ, Heaton DC. Genomic diversity correlates with clinical variation in Ph-negative chronic myelogenous leukemia. Nature 320:281-282, 1986.
71. Pugh WC, Pearson M, Vardiman JW, Rowley JD. Philadelphia chromosome-negative chronic myelogenous leukemia: a morphological reassessment. Br J Haematol 60:457-467, 1985.
72. Travis LB, Pierre RV, Dewald GW. Ph negative chronic granulocytic leukemia: a non entity. Am J Clin Pathol 85:186-193, 1986.
73. Kantarjian HM, Keating MJ, Walters RS. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 58:2023-2030, 1986.
74. Swolin B, Weinfeld A, Westin J, Waldenstrom J, Magnusson B. Karyotypic evolution in Ph positive chronic myeloid leukemia in relation to management and disease progression. Cancer Genet Cytogenet 18:65-79, 1985.
75. Montefusco E, Alimena G, Lo Coco F, De Cuia MR, Wang Y-Z, Aloe Spiriti MA, et al. Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. Ann Hematol 65:17-22, 1992.
76. Kurzrock R, Kantarjian HM, Gutterman JU, Talpaz M. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangment: a chronic myeloid leukemia with a distinct clinical course. Blood 75:445-452, 1990.
77. Watamore AE, Potter AM, Sokal RJ. Value of cytogenetic studies in predicting of acute phase of CML. Cancer Genet Cytogenet 21:343-345, 1986.
78. Sokal J, Gomez O, Baccarani M, Tura S, Clarkson BD, Cervantes F, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 72:294-298, 1988.
79. Mitelman F, Levan G, Nilsoon PG, Brandt L. Non-random karyotypic evolution in chronic myeloid leukemia. Int J Cancer 18:24-30, 1976.
80. Lower SD. Karyotypic evolution in chronic myeloid leukemia. Int J Cancer 18:24-30, 1976.
81. Sandberg AA. The Chromosome Changes in Human Cancer and Leukemia. New York: Elsevier, 1980; 183-201.
82. Sessarego M, Panarello C, Coviello DA. Karyotype evolution in CML: high frequency of translocation other than Philadelphia. Cancer Genet Cytogenet 25:73-80, 1987.
83. Sadamori N, Gomez GA, Sandberg AA. Therapeutic and prognostic value of initial chromosomal findings at the blastic phase of Ph-positive chronic myeloid leukemia. Cancer Genet Cytogenet 15:17-24, 1985.
84. O'Malley FM, Garson OM. Chronic granulocytic leukemia: correlation of blastic transformation type with karyotypic evolution. Am J Hematol 20:313-323, 1985.
85. Parreira L, Kearney L, Rassool F, Babapulle VB, Matutes E, Parreira A, et al. Correlation between chromosomal abnormalities and blast phenotype in the blast crisis of Ph-positive CGL. Cancer Genet Cytogenet 22:29-34, 1986.
86. Oshimura M, Ohyashiki K, Terada H, Variant translocations in CML and their incidence, including two cases with sequential myeloid and lymphoid crisis. Cancer Genet Cytogenet 5:187-201, 1982.
87. Sadamori N, Matsunaga M, Yao E. Chromosomal characteristics of chronic and blast phases of Ph-positive chronic myeloid leukemia. Cancer Genet Cytogenet 15:17-24, 1985.
88. Alimena G, De Cuia MR, Diverio D, Dalla Piccola B, Mandelli F. The karyotype of blastic crisis. Cancer Genet Cytogenet 23:39-50, 1987.
89. Cervantes F, Ballestra F, Mila M, Rozman C. Cytogenetic studies in blast crisis of Ph-positive chronic granulocytic leukemia: results and prognostic evaluation in 52 patients. Cancer Genet Cytogenet 21:239-246, 1986.
90. Singh S, Wass J, Vincent PC, Young GAR, Gunz FW. Significance of secondary cytogenetic changes in patients with Ph-positive chronic granulocytic leukemia in the acute phase. Cancer Genet Cytogenet 21:209-220, 1986.
91. Rowley JD. Ph-positive leukemias, including chronic myelogenous leukemia. Clin Haematol 9:55-86, 1980.
92. Yao E. Chromosomal abnormalities in lymphoid crises of chronic myelogenous leukemia. Cancer Genet Cytogenet 16:235-243, 1985.
93. Ohyashiki K, Ohtaki K, Ohyashiki JH. 14q + in Ph-positive chronic myelogenous leukemia. Cancer Genet Cytogenet 22:257-263, 1986.
94. Cline MJ. The molecular basis of leukemia. N Engl J Med 330:328-336, 1994.
95. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and clonal evolution of the blast crisis in chronic myelocytic leukemia. Proc Natl Acad Sci USA 86:6783-6785, 1989.
96. Foti A, Ahuja HG, Allen SL, Koduri P, Schuster MW, Schulman P, et al. Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blastic crisis. Blood 77:2441-2444, 1991.
97. Bi S, Barton CM, Lemoine NR, Cross NCP, Goldman JM. Retroviral transduction of Philadelphia positive chronic myeloid leukemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation. Exp Hematol 22:95-99, 1994.
98. Clarkson B, Strife A. Linkage of proliferative and maturation abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 7:1683-1721, 1993.
99. Ogawa M, Friend J, Sakai Y, Strife A, Clarkson B. Studies of cellular proliferation in human leukemia. Cancer 25:1031-1049, 1970.
100. Gavosto F. Granulopoiesis and cell kinetics in chronic myelogenous leukemia. Cell Tissue Kinet 7:151-163, 1974.
101. Fauser AA, Messner HA. Granulocytopoietic colonies in human bone marrow, peripheral blood, and cord blood, Blood 52:1243-1247, 1978.
102. Moore MAS, Williams N, Metcalf D. In vitro colony formation by normal and leukemic human hemopoietic cells: characterization of the colony forming cells. J Natl Cancer Inst 50:603-623, 1973.
103. Olofsson T, Olsson I. Granulocytopoiesis in chronic myeloid leukemia. II. Serial cloning of blood and bone marrow cells in agar colture. Blood 48:351-360, 1976.
104. Goldman JM. In vitro colony forming cells and colony stimulating factors in chronic granulocytic leukaemia. Br J Cancer 30:1-5, 1974.
105. Chevernick PA, Ellis CD, Pan SF, Lawson AL. Human leukemic cells: in vitro cell growth of colonies containing the Philadelphia (Ph') chromosome. Science 174:1134-1136, 1971.
106. Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 308:1493-1497, 1983.
107. Dube ID, Kalousek DK, Coulombel L, Gupta CM, Eaves CJ, Eaves AC. Cytogenetic studies of early myeloid progenitor compartments in Ph'-positive chronic myeloid leukemia (CML). II: Long term culture reveals the persistence of Ph'-negative progenitors in treated as well as newly diagnosed patients. Blood 63:1172-1177, 1984.
108. Eaves AC, Cashman JD, Gaboury LA, Kalousek DK, Eaves CJ. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci USA 83:5306-5310, 1986.
109. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myeloid leukemia. Nature 328:342-344, 1987.
110. Verfaillie CM, McCarthy JB, McGlave PB. Mechanism underlyng abnormal traffiking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to the basement membrane components lamin and collagen type IV. J Clin Invest 90:1232-1241, 1992.
111. Dowding L, Guo A, Osterholz J, Siczkowski M, Goldman JM, Gordon MY. Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78:499-505, 1991.
112. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, et al. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor: a novel application for inhibitors of IL-1 activity. Blood 78:1476-1484, 1991.
113. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 44:153-205, 1989.
114. Bagby GC, Dinarello CA, Neerhout RC, Ridgway D, McCall E. Interleukin-1 dependent paracrine granulopoiesis in chronic granulocytic leukemia of the juvenile type. J Clin Invest 82:1430-1436, 1988.
115. Cozzolino F, Rubatelli A, Aldinucci D, Sitia R, Torcia M, Show A. Di Guglielmo R. Interleukin-1 as an autocrine growth factor for acute myeloid leukemia cells, Proc Natl Acad Sci USA 86:2369-2373, 1989.
116. Estrov Z, Markowitz AB, Kurzrock R, Wetzel M, Kantarjian HM, Ferrajoli A, et al. Suppression of chronic myelogenous leukemia growth by interleukin-4. Leukemia 7:214-220, 1993.
117. Wetzel M, Kurzrock R, Lowe DG, Kantarjian HM, Gutterman JU, Talpaz M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood 78:2400-2406, 1991.
118. Estrov Z, Kurzrock R, Talpaz M. Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. Leuk Lymph 10:407-418, 1993.
119. Tura S, Baccarani M, Zaccaria A. Chronic myelogenous leukemia. Haematologica 71:169-176, 1986.
120. Spiers ASD. Chronic granulocytic leukemia. Med Clin North Am 68:713-727, 1984.
121. Clough V, Geary GC, Hasmi K, Knowlson T. Myelofibrosis in chronic granulocytic leukemia. Br J Haematol 42:515-526, 1979.
122. Hayhoe FGJ, Flemans RJ, Cowley DC. Acquired lipidosis of marrow macrophages, birefringent blue cristals and Gaucher-like cells, sea-blue histiocytes and grey-green crystals. J Clin Pathol 32:420-428, 1979.
123. Cervantes F, Rozman C, Brugues R, Lianas I. Iron stores in chronic granulocytic leukemia at presentation, Scand J Haematol 32:469-474, 1984.
124. De Brackeleer M. Variant Ph translocations in CML: is there an uneven geographic distribution? Cancer Genet Cytogenet 23:167-170, 1986.
125. Hagemeijer A, Bartram CR, Smith EME, van Agthoven AJ, Bootsma D. Is the chromosomal region 9q34 always involved in variants of the Ph translocation? Cancer Genet Cytogenet 13:1-16, 1984.
126. Ishihara T, Minamihisamatsu M, Toseyi H. Chromosome 9 in variant Ph translocations. Cancer Genet Cytogenet 14:183-184, 1985.
127. Bernstein R, Pinto MR, Rosendorff J, et al. 'Masked' Ph chromosome abnormalities in CML: a report of two unique cases. Blood 63:399-406, 1984.
128. Ohyashiki K, Ohyashiki J, Otaki K, et al. Four cases with complex Philadelphia translocations, including one with appearance de novo of a 'masked' Ph. Cancer Genet Cytogenet 26:105-115, 1987.
129. Langer PR, Waldrop AA. Ward DC. Enzymatic synthesis of biotin labeled polynucleotides: novel nucleic acid affinity probes. Proc Natl Acad Sci USA 78:6633-6637, 1978.
130. Landergent JE, Jensen in de Wal N, Baan RA, Hoeijmakes JHJ, van der Ploeg M. 2-Acetylaminofluorene-modified probes for the indirect hybridocytochemical detection of specific nucleic acid sequences. Exp Cell Res 153:61-72, 1984.
131. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high sensitive, fluorescence hybridization. Proc Natl Acad Sci USA 83:2934-2938, 1986.
132. Tkachuk DC, Westbrook CA, Andreeff M, Donion TA, Clearly ML, Suryanarayan K, et al. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. Science 250:559-562, 1990.
133. Anastasi J, Le Beau MM, Vardiman JW, Fernald AA, Larson RA, Rowley JD. Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method. Blood 79:1796-1801, 1992.
134. Zhao L, Kantarjian HM, Van Oort J, Trujillo JM, Liang IC, Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment. Leukemia 7:168-171, 1993.
135. Durnam DM, Anders KR, Fisher L, O'Quingley J, Bryant AM, Thomas ED. Analysis of the origin of marrow cells in bone marrow transplant recipiens using a Y chromosome-specific in situ hybridization assay. Blood 74:2220-2226, 1989.
136. Anastasi J, Vardiman JW, Rudinsky R, Patel M, Nachman J, Rubin CM, Le Beau MM. Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: an analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia. Blood 77:2456-2462, 1991.
137. Jenkins RB, Le Beau MM, Kraker WJ, Borell TJ, Stalboerger PG, Davis EM, et al. Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. Blood 79:3307-3315, 1992.
138. Chen Z, Morgan R, Stone JF, Sandberg AA. FISH: a useful tecnique in the verification of clonality of random chromosome abnormalities. Cancer Genet Cytogenet 66:73-74, 1993.
139. Poddighe PJ, Moesker O, Smeets D, Award BH, Ramaekers FCS, Hopman AHN. Interphase cytogenetics of haematological cancer: comparison of classical karyotyping and in situ hybridization using a panel of eleven chromosome specific DNA probes. Cancer Res 51:1959-1967, 3991.
140. Ried T, Baldini A, Rand T, Ward DC. Simultaneous visualization of seven different DNA probes by in situ hybridization using combinatorial fluorescence and digital imaging microscopy. Proc Natl Acad Sci USA 89:1388-1392, 1992.
141. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 63:789-799, 1984.
142. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25:49-61, 1988.
143. Sokal JE, Gomez GA, Baccarani M, Tura S, Clarkson BD, Cervantes F, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 72:294-298, 1988.
144. Sokal JE, Baccarani M, Tura S, Fiacchini M, Cervantes F, Rozman C, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia. Relevance to bone marrow transplantation. Blood 66:1352-1357, 1985.
145. Tura S, Baccarani M, Corbelli G. Staging of chronic myeloid leukemia. Br J Haematol 47:105-119, 1981.
146. Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood 60:1298-1304, 1982.
147. Kantarjian HM, Smith TL, Mc Credie KB, Keating MJ, Walters RS. Talpaz M, et al. Chronic myelogenous leukemia: a multivariate analysis of the association of patient characteristics and therapy with survival. Blood 66:1326-1335, 1985.
148. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, Mc Credie KB. Proposal for a simple synthetic prognostic staging system in chronic myelogenous leukemia. Am J Med 88:1-8, 1990.
149. Schaefer-Rego K, Dudek H, Popenoe D, Arlin Z, Mears JG, Bank A, Leibowitz D. CML patients in blast crisis have breakpoints localized to specific region of the BCR. Blood 70: 448-455, 1987.
150. Mills KI, MacKenzie ED, Birnie GD. The site of breakpoint within the bcr is a prognostic factor in Philadelphia positive CML patients. Blood 72:1237-1241, 1988.
151. Eisemberger A, Silver R, Soper L, Arlin Z, Coleman M, Bernhardt B, Benn P. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia 2:642-647, 1988.
152. Mills KI, Hynds SA, Burnett AK, MacKenzie ED, Birnie GD. Further evidence that the site of breakpoint in the major breakpoint cluster region (M-bcr) may be a prognostic indicator. Leukemia 3:837-840, 1989.
153. Grossman A, Silver RT, Arlin Z, Coleman M, Camposano E, Gascon P, Benn PA. Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for exon 3 in determining disease duration in chronic myeloid leukemia. Am J Hum Genet 45:729-739, 1989.
154. Shtalrid M, Talpaz M, Kurzrock R, Kantarjian HM, Trujillo J, Gutterman JU, et al. Analysis of breakpoints within the bcr and their correlation with the clinical course of Philadelphiapositive chronic myelogenous leukemia. Blood 72:485-490, 1988.
155. Teffer A, Bren GD, Wagner KW, Schaid DJ, Ash RC, Thipodeau DN. The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia. Leukemia 4:839-842, 1990.
156. Jaubert J, Martiat P, Dowding C. Ifrah N, Goldman JM. The position of the M-bcr breakpoint does not predict the duration of the chronic phase or survival in chronic myelogenous leukaemia. Br J Haematol 74:30-35, 1990.
157. Morris SW, Daniel L, Ahtned CMI, Elian A, Lebowitz P. Relationship of the bcr breakpoint to chronic phase duration, survival and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood 75:2035-2041, 1990.
158. Tein HF, Wang CH, Chen YC. Shen MC, Wu HS, Lee FY, et al. Chromosome and bcr rearrangment in chronic myelogenous leukemia and their correlation with clinical states and prognosis of the disease. Br J Haematol 75:469-475, 1990.
159. Przepiorka D. Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with the disease phase or prognosis. Cancer Genet Cytogenet 36:117-122, 1988.
160. Ogawa H, Sugiyama H, Soma T, Massaocka T, Kishimoto S. No correlation between locations of bcr breakpoints and clinical states in Ph-positive CML patients. Leukemia 3:492-496, 1989.
161. Morgan GJ, Hernandez A, Chan LC, Hughes T, Martiat P, Weidemann LM. The role of alternative splicing patterns of BCR/ABL transcripts in the generation of the blast crisis of chronic myeloid leukemia. Br J Haematol 76:33-44, 1990.
162. Tanaka K, Hashimoto T, Oguma N, Dohy H, Katnoda N. Influence of M-BCR breakpoint sites on the duration of chronic phase in 100 patients with chronic myelocytic leukemia. Cancer Genet Cytogenet 70:39-47, 1993.
163. Altman AJ, Palmer CG, Bachner RL. Juvenile chronic granulocytic leukemia: a panmyelopathy with predominant monocytic involvement and circulating monocyte colony-forming cells. Blood 43:341-350, 1974.
164. Estrov Z, Grunberger T, Chan HSL, Freedman MH. Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. Blood 67:1382-1387, 1986.
165. Emanuel PD, Bates LJ, Casteberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77:925-929, 1991.
166. Freedman MH, Cohen A, Grunberger T, Bunin N, Shahidi N, Lau A, Estrov Z. Central role of tumor necrosis factor and GM-CSF in the pathogenesis of juvenile chronic myelogenous leukemia. Br J Haematol 80:40-48, 1992.
167. Schirò R, Longani D, Rossi V, Maglia O, Dani A, Arsura M, et al. Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist. Blood 83:460-465, 1994.
168. Altman AJ, Schwartz AD. Malignant Diseases of Infancy, Childhood, and Adolescence. Saunders: Philadelphia, 1983; 228-229.
169. Canellos GP, Young RC, Nieman PE, De Vita VT. Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulphan. Blood 45:197-203, 1975.
170. Kennedy BJ. Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 29:1052-1056, 1972.
171. Gallon DAG. Chemotherapy of chronic myelocytic leukemia. Semin Hematol 6:323-343, 1969.
172. Hehlmann R, Heimpel H, Hasford DJ, Kolb HJ, Pralle H and the German CML Study Group. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyura. Blood 82:398-407, 1993.
173. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol 234:132-143, 1986.
174. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: A coincise update. Blood 82:691-703, 1993.
175. Bolin RW, Robinson WA. Sutherland J, Hamman RF. Busulfan versus hydroxyurea in long therapy of chronic myelogenous leukemia. Cancer 50:1683-1686, 1982.
176. Hehlmann R, Anger B, Messerer D, Zankovich R, Bergmann L, Kolb HJ. Randomized study on the treatment of CML in chronic phase with busulfan versus hydroxyurea versus interferon-α. Blut 56:87-91, 1988.
177. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia. Cancer 54:333-338, 1984.
178. Talpaz M, Kantarjian HM, McCredie K, Keating MJ, Trujillo JM, Gutterman JU. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69:1280 1288, 1987.
179. Talpaz M, Kantarjian HM, McCredie KB, Trujilio JM, Keating M, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 314:1065-1069, 1986.
180. Talpaz M, Kantarjian HM, Kurzrock R, Trujilio JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Ann Intern Med 114:532-538, 1991.
181. Neiderle N, Kloke O, Wandl UB, Becher R, Moritz T, Opalka B. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. Leuk Lymph 9:111-119, 1993.
182. Ozer H, George L, Schiffer CA, Rao K, Wuster-Hill DH, Arthur DD, et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated' Philadelphia chromosome-positive chronic phase chronic myelogenous leukemia effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 82:2975-2984, 1993.
183. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, et al. Interferon alpha-2b as therapy for patients with Ph'-positive chronic myelogenous leukemia. Eur J Haematol 45:25-28, 1990.
184. Strander H, Cantell K. Production of interferon by human leucocytes in vitro. Ann Med Exp Biol Fenn 44:265-269, 1966.
185. Strander H, Mogensen KE. Production of human lymphoblastoid interferon. J Clin Microbiol 1:116-118, 1975.
186. Weck PK, Appereson S. Comparison of the antiviral activities of various cloned human interferon alpha subtypes in mammalian cell cultures. J Gen Virol 57:233-237, 1981.
187. Oladipupo-Williams CK, Svet-Moldavskaya I, Vilcek J. Inhibitory effect of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemia granulocytic progenitors. Oncology 38: 356-360, 1981.
188. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of Chronic Myeloid Leukemia. N Engl J Med 330:820-825, 1994.
189. Wussow PV, Helmann R, Jakschies D, Hochhaus T, Witte T, Ansari H, et al. Recombinant IFN-alpha-2a is more immunogenic than recombinant IFN-alpha-2b in patients with CML. Ann Hematol 65:143, 1992.
190. Wussow PV, Jakschies D, Freud M, Hehlmann R, Brockhaus F, Hochkeppel H, et al. Treatment of anti-recombinant interferon-alpha2 antibody positive CML patients with natural interferon-alpha. Br J Haematol 78:210-216, 1991.
191. Nolte KU, Peterson J, Schwartz B, Pestka S, VonWussow P. Subtype specificity of therapy-induced human recombinant IFN-alpha-2 antibodies. J Interferon Res 12:180, 1992.
192. Feldmane G, Strozha I, Bondare D, Duks A, Petuhovs V. Reaferon in treatment of chronic myelogenous leukemia: its antigenicity in correlation with clinical efficiency. J Interferon Res 11:260, 1991.
193. Shtalrid M, Iugassy G, Berrebi A. Treatment of chronic myeloid leukemia with interferon alpha (Roferon A): results of the Israeli study group on CML. Haematologica 76(Suppl.4):119, 1991.
194. Freund M, Fonatsch C, Von Wussow P, Hiddemann W, Koch O, Kleine HD, et al. Interferon in the treatment of CML: The Hannover experience. Ann Hematol 65:97, 1992.
195. 2b) in patients with chronic myelogenous leukemia. J Interferon Res 14:217-219, 1994.
196. 2 genes in humans. J Interferon Res 14:183-185, 1994.
197. Kurzrock R, Talpaz M, Kantarjian HM, Walters R, Saks S, Trujillo JM, Gutterman JU. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 70:943-947, 1987.
198. Ratain MJ, Larson RA, Hooberman A, Pape L, Wallemberg J, Mareus S. Phase II study of recombinant beta interferon in chronic myelogenous leukemia. Blood 72:797a, 1988.
199. Wandl UB, Kloke O, Nagel-Hiemke M, Moritz T, Becher R, Opalka B, et al. Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukemia. Br J Haematol 81:516-519, 1991.
200. Guilhot F, Dreyfus B, Brizard A, Huret JL, Tanzer J. Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha-2a and hydroxyurea with or without low dose cytosine arabinoside. Leuk Lymph 4:49-55, 1991.
201. Morra E, Lazzarino M, Alimena G, Liberati AM, Grignani F, Mandelli F, Bernasconi C. The role of interferon in the treatment of chronic myelogenous leukemia: results and prospects. Leuk Lymph 6:305-315, 1992.
202. Cannistra S, Tantravahi R, Robertson MJ, Griffin J, Canellos GP. Low-dose cytosine arabinoside induces cytogenetic remissions in patients with stable chronic myeloid leukemia. Blood 76:259a, 1990.
203. Sokal JE, Leong SS, Gomez GA. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia. Cancer 59:197-202, 1987.
204. Imanishi J, Tanaka A. Experimental research for clinical applications of interferon. Jpn J Cancer Chemother 11:53-59, 1984.
205. Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α, and low-dose cytarabine. J Clin Oncol 10:772-778, 1992.
206. Ferrajoli A. Liberati AM, Caricchi P, Donti E, Morra E, Lazzarino M, et al. Interferon-a plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukemia patients. Eur J Haematol (in press).
207. Arthur CK, Ma DDF. Combined interferon alfa-2a and cytosine arabinoside as first line treatment for chronic myeloid leukemia. Acta Haematol 89:15-21, 1993.
208. Guilhot F, Tanzer J, Bouters F, et al. A multicentric randomized study of alpha 2b interferon and hydroxyurea with or without cytosine-arabinoside in previously untreated patients with Ph + CML. Haematologica 76:64-72, 1991.
209. Clarkson BD. Chronic myelogenous leukemia: is aggressive treatment indicated? J Clin Oncol 3:135-139, 1985.
210. Kantarjian HM, Talpaz M, Keating MJ, Estey EH, O'Brien S, Beran M, et al. Intensive chemotherapy induction followed by interferon-alpha manteinance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 68:1201-1207, 1991.
211. Meloni G, De Fabritiis P, Alimena G, Malagnina F, Montefusco E, Sandrelli A, et al. Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukemia in chronic phase. Bone Marrow Transplant 4:92-94, 1989.
212. McGlave PB, De Fabritiis P, Deisseroth A, Goldman JM, Barnett M, Reiffers J, et al. Autologous transplants for chronic myelogenous leukemia: results from eight transplant groups. Lancet 343:1486-1488, 1994.
213. Barnett MJ, Eaves CJ, Phillips GL, Gascoyne RD, Hogge DE, Horsman DE, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 84:724-732, 1994.
214. Verfaillie CM, Miller WJ, Boylan K, McGlave PB. Selection of benign hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79:1003-1010, 1991.
215. O'Brien SG, Kirkland MA, Davidson RJ, McDonald C, Goldman JM. Antisense oligodeoxinucleotides for in vitro purging of autologous bone marrow in chronic phase chronic myelogenous leukemia. Blood 85(Suppl.1):436a, 1993.
216. Notter M, Maurer J, Krackhardt A, Henkel B, Henze K, Bochert G, et al. Ex vivo elimination of chronic myelogenous leukemia (CML) cells following activation and targeting of host T cells by combination of cytokines and CD3 monoclonal antibodies. Blood 82:975a, 1993.
217. Simonsson B, Oberg G, Killander A, Bjoreman M, Barkholm M, Gahrton G, et al. Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia. Stem Cells 11(suppl.3):73-76, 1993.
218. Carella AM, Gaozza E, Raffo MR, Carlier P, Frassoni F, Valbonesi M, et al. Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood autograft and cyclosporine A. Leukemia 5:517-521, 1991.
219. Carella AM, Podestà M, Frassoni F. Raffo MR, Pollicardo N, Pungolino E, et al. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 12:267-271, 1993.
220. Goldman JM, Szydlo R, Horowitz MM, Gall RP, Ash RC, Atkinson K, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235-2238, 1993.
221. Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A. Andersson BS, et al. Effect of prior Interferon alpha therapy on the outcome of allogeneic bone marrow transplantation in chronic myelogenous leukemia. J Clin Oncol 11:1055-1061, 1993.
222. Italian Cooperative Study Group on CML. Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukemia in chronic phase: a comparison of transplant versus no-transplant in a cohort of 258 patients first seen in Italy between 1984 and 1986. Br J Haematol 85:292-299, 1993.
223. Buckner C, Clift R, Appelbaum F, Thomas E. A randomized study comparing two transplant regimens for CML in chronic phase. Blood 88(suppl.1):72a, 1992.
224. Aversa F, Pelicci PG, Terenzi A, Carotti A, Felicini R, Mencarelli A, et al. Results of T depleted BMT in chronic myelogenous leukemia after a conditioning regimen that included thiotepa. Bone Marrow Transplant 7:24-27, 1991.
225. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806-814, 1988.
226. Arcese W, Goldman JM. D'Arcangelo E, Schattenberg A, Nardi A, Apperley JF, et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. Blood 15:3211-3219, 1993.
227. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 84:3603-3612, 1994.
228. Kolb H, Mittermuller J, Clemm C, Holler E, Ledrerose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2467, 1990.
229. Porter DL, Roth MS, Garigle C, Ferrara JML, Antin JH. Induction of graft-versus-host-disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100-106, 1994.
230. Garicochea B, Van Rhee F, Spencer A, Chase A, Lin F, Cross NCP, Goldman JM. Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismached BMT: recovery of donor-type haemopoiesis predicted by non-isotopic in situ hybridization (ISH). Br J Haematol 88:400-402, 1994.
231. Kumar L. Donor leukocyte infusions for relapse in chronic myelogenous leukaemia. Lancet 344:1101-1102, 1994.
232. Giralt S, Escudier S. Kantarjian HM, Deisseroth A, Freireich EJ. Preliminary results of treatment with filgastrim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantion. N Engl J Med 329:757-761, 1993.
233. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kerman NA. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 81:543-550, 1993.
234. Coleman M, Silver RT, Pajak TF, Covelli F, Rai KR, Kostimas JE, Glindelwell O, Holland JF. Therapy for terminal phase chronic granulocytic leukemia: Cancer and Leukemia Group B studies. Blood 55:29-36, 1980.
235. Walters RS, Kantarjian HM, Keating MJ, Talpaz M. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuos vincristine and adriamycin infusions plus high dose decadron. Cancer 60:1708-1712, 1987.
236. Kantarjian HM, Talpaz M, Kantoyannis D, Gutterman JU, Keating MJ, Estey EH, et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phase with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 10:398-405, 1992.
237. de Witte T, Raymakers R, de Pauw B, Haanen C. Repetitive cycles of cytoreductive therapy followed by stem cell autografting for non-lymphoblastic transformation of chronic granulocytic leukemia. Scand J Haematol 35:421-426, 1985.
238. Lee MS, Chang KS, Cabanillas F, Frereich EJ, Trujillo JM, Stass SA. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 237:175-180, 1987.
239. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON. McCormick FP. Diagnosis of chronic myelogenous leukemia and acute leukemia by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 85:5689-5702, 1988.
240. Lee MS, Chang KS, Freireich EJ, Trujillo JM, Stass SA. Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. Blood 72:893-898, 1988.
241. Opalka B, Wandl UB, Becher R, Kloke O, Nagel-Hiemke M, Moritz T. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha alone or in combination with interferon gamma. Blood 78:2188-2193, 1991.
242. Oguma N, Shigeta C, Takauchi K, Tanaka K, Kamada N, Kawano H, Kuramoto A. Molecular elimination of the minimal Ph clone with IFN alpha in CML. Lancet 339:557-558, 1992.
243. Lee MS, LeMaistre A, Kantarjian HM, Talpaz M, Freireich EJ, Trujillo JM, Stass SA. Detection of two alternative bcr/abl mRNAs and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood 73:2165-2168, 1989,
244. Lee MS, Kantarjian HM, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following Interferon therapy. Blood 79:1920-1923, 1992.
245. Gabert J, Lafage M, Maranichi D, Thuret I, Carcassonne Y, Mannoni P. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukemia patients after bone-marrow transplantation. Lancet 2:1125-1128, 1989.
246. Roth MS, Antin JH, Bingham EL, Ginsburg D. Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone-marrow transplant for chronic myelogenous leukemia. Blood 74:882-886, 1989.
247. Hughes TP. Morgan GJ, Martial P, Goldman JM. Detection of residual leukemia after bone marrow transplantation for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 77:874-878, 1991.
248. Malinge MC, Mahon FX, Delfau MH, Daheron L, Kitzis A, Guilhot F, et al. Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukemia under interferon therapy, Br J Haematol 82:701-706, 1992.
249. Thompson JD, Brodsky I, Yunis JJ. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood 79:1629-1635, 1992.
250. Cross NP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929-1936, 1993.
251. BCR- ABL: determination of individual colonies with the polymerase chain reaction. Cancer Res 53:3289-3293, 1993.
252. O'Brien S, Keating M, Kantarjian HM, Talpaz M, Beran M, Stass SA. et al. Homoharringtonine induces apoptosis in chronic myelogenous leukemia cells. Blood 85(suppl.1):2203a, 1993.
253. Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, et al. Genetic marking shows that Ph + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83:3068-3076, 1994.